Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Adds Diabetes Class Warning To Abilify Labeling; “Paucity” Of Reports Cited For Antipsychotic

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol and Otsuka had been seeking to persuade FDA that the atypical antipsychotic should be exempt from a class-wide hyperglycemia warning. Bristol will continue discussions with the agency as new data become available.

You may also be interested in...



Zyprexa Growth Strategy Includes Discussing Weight Gain With Doctors

Marketing efforts include helping physicians manage weight gain associated with use of the antipsychotic and identify "appropriate" patients for Zyprexa therapy. Lilly estimates 30% of patients will gain "a lot of weight" while taking olanzapine.

Zyprexa Growth Strategy Includes Discussing Weight Gain With Doctors

Marketing efforts include helping physicians manage weight gain associated with use of the antipsychotic and identify "appropriate" patients for Zyprexa therapy. Lilly estimates 30% of patients will gain "a lot of weight" while taking olanzapine.

Zyprexa On More Level Playing Field After Diabetes Class Label Changes, Lilly Says

Physicians will be more inclined to prescribe atypical antipsychotics based on efficacy rather than side effects now that "virtually" all NDA holders have revised labeling, Lilly says. Pfizer (Geodon) remains the lone holdout.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel